<?xml version="1.0" encoding="UTF-8"?>
<p>Initiation of immunosuppressive agents has been associated with increased risk for severe disease with respiratory viruses. However, no evidence routinely discontinuing treatment is of any benefit. Therefore, the plan to discontinue prednisone, biologics, or other immunosuppressive drugs in the setting of COVID-19 must be determined on a case-by-case basis. COVID-19-negative patients with underlying conditions requiring treatment with these agents should not be taken off suddenly, as discontinuing of these medications may result in loss of response when the agent is reintroduced. Statements from different medical societies support the approach of continuing immunomodulatory therapy in patients without infection [
 <xref rid="R12" ref-type="bibr">12</xref>].
</p>
